-
A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance.
30 Jan 2025 14:50 GMT
Cx bladder monitor (CxM) is a urine test with a proven high sensitivity and negative predictive value in bladder cancer surveillance. The aim of this retrospective study was to report on the outcomes of our newly implemented bladder cancer surveillance …
-
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
30 Jan 2025 13:13 GMT
… or progression after treatment.
“The current treatment options for patients … bladder cancer (NMIBC)
Abstract #: TPS886
Poster #: J14
Clinical Trial … U.S. Food and Drug Administration (FDA) based on its … expedite the review of drugs to treat serious conditions …
-
UroGen Pharma to Present at Upcoming Investor Conferences
30 Jan 2025 13:13 GMT
… 90 days.
About UroGen Pharma Ltd.
UroGen is a … therapeutic profiles of existing drugs. UroGen’s sustained release … to medications, making local therapy a potentially more effective treatment … -grade non-muscle invasive bladder cancer are designed to ablate …
-
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
29 Jan 2025 13:48 GMT
… FDA-approved immunotherapy for non-muscle invasive bladder cancer … and developing innovative treatments that are more … Trial-Characterizing-the-Pharmacokinetic
https://www.accessdata.fda … to patients, potential treatment outcomes for patients, the …
-
Urothelial Carcinoma FDA Approvals, Clinical Trials, Emerging Drugs And Companies | Delveinsight
29 Jan 2025 04:36 GMT
… Urothelial Carcinoma pipeline drug profiles, including … Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, … Urothelial Carcinoma clinical trials, emerging drugs, and market … studied in the treatment of bladder cancer, prostate cancer, …
-
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
27 Jan 2025 14:13 GMT
… treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer … . ANKTIVA has improved pharmacokinetic properties, longer persistence … clinical trials, (v) whether clinical trials will … of prescription drugs to FDA.
Visit www.FDA.gov…
-
Researchers use “hallmarks of cancer” to understand tumour growth
30 Jan 2025 13:06 GMT
… likely to respond to certain treatments."
While this debate might … management of 33 bladder cancer patients in the DUTRENEO trial and found that … identifying hallmark ‘hotspots’ linked to drug resistance, we can improve how …
-
Pfizer reports positive outcomes from trial of mCRC combination therapy
27 Jan 2025 12:58 GMT
… survival.”
The US Food and Drug Administration granted accelerated approval to … CREST trial assessing sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment … , high-risk non-muscle invasive bladder cancer, met its primary endpoint.
Sign …
-
Ethnicity and race as modifiers of the association between patient sex and stage at diagnosis of bladder cancer.
24 Jan 2025 12:05 GMT
With over 80,000 projected new diagnoses in 2024, bladder cancer remains a significant public health concern. Given the absence of routine screening protocols, identifying high-risk populations becomes crucial for early detection and intervention. This …
-
Bladder cancer: Shaping the future of global clinical trials
24 Jan 2025 08:58 GMT
… based treatments for muscle-invasive bladder cancer … and Alliance Pharma. Their innovative trials investigate a … spectrum of cutting-edge therapies, from antibody-drug … the complexities of bladder cancer treatment.
Breakthrough innovations …
About
© 1995-2025